You just read:

Bayer Initiates Phase 3 Trial of Xofigo® (radium Ra 223 dichloride) Injection in Combination with Abiraterone Acetate for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Bone Predominant Metastatic Castration-Resistant Prostate Cancer

News provided by

Bayer HealthCare Pharmaceuticals Inc.

02 Apr, 2014, 02:30 ET